Brief: Cognition Therapeutics Q2 Operating Expenses USD 11.817 Mln
08/08/2023 12:15
Aug 8 (Reuters) - Cognition Therapeutics Q2 operating expenses USD 11.817 million. * Q2 income from operations USD -11.817 million * Q2 pretax profit USD -4.726 million * Q2 net income USD -4.726 million
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB